Ivosidenib is a targeted therapy for specific gene mutations, primarily used to treat relapsed or refractory acute myeloid leukemia (AML) with IDH1 mutations. Its price varies depending on region, health insurance policy, and purchase channel. The domestic market price is typically between 20,000 and 40,000 RMB per box (28 tablets), but specific prices should be confirmed with hospitals or authorized pharmacies.
Main Factors Affecting Price
Regional Differences: Pricing strategies, tariffs, and distribution costs in different countries or regions may cause price fluctuations. For example, overseas purchases or imported versions may incur increased costs due to shipping and agency fees.
Health Insurance Policy: In some regions, vosidenib is covered by health insurance, significantly reducing the patient's out-of-pocket expenses, but this requires meeting specific indications and approval conditions.
Dosage and Specifications: Dosage may be adjusted based on the patient's weight and treatment stage, resulting in varying overall treatment costs.
Precautions for Use
Prescription Drug Must Be Used Under Doctor's Prescription: Ivosidenib is a prescription drug and must be used under the guidance of a professional physician. Dosage adjustments or discontinuation of the medication should not be made without professional medical advice.
Side effect monitoring: Common adverse reactions include fatigue, joint pain, and diarrhea. Severe cases may lead to differentiation syndrome (requiring emergency treatment).
Regular follow-up: During treatment, blood tests and imaging examinations are necessary to assess efficacy and drug tolerability.
Medical treatment and medication purchase recommendations:
Choose legitimate channels: Purchase medications from hospitals or authorized pharmacies to avoid the risk of counterfeit drugs from unofficial sources.
Apply for assistance programs: Some charitable organizations or pharmaceutical companies offer patient assistance programs that can alleviate financial burdens for eligible individuals.
Multidisciplinary treatment: It is recommended to develop a personalized treatment plan based on the results of hematology or oncology specialists and genetic testing.
For specific pricing or eligibility information, it is recommended to consult the hospital directly or check local policies through the "National Medical Insurance Service Platform." The use of targeted drugs involves complex medical judgments; please always follow professional medical advice.
